Harrow Partners with Healthcare Market Access Technology Platforms to Support Launch of Vevye

Harrow announced that it has partnered with three healthcare technology platforms to expand US availability of dry eye drug Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) ophthalmic solution based on a water-free semifluorinated alkane (SFA) eye drop technology. 

Vevye, which is dispensed in a 10 microliter drop, is the first and only cyclosporine-based product indicated for treating both signs and symptoms of dry eye disease (DED). 

Harrow’s three market access partnerships for Vevye include:

• PhilRx, a patient access platform that provides end-to-end visibility into the entire prescription life cycle. Using the PhilRx platform is designed to simplify the prior authorization process (PA) for physicians by providing one-click submission of PAs, streamlining the insurance coverage process for patients, and increasing the chances of insurance reimbursement. 
• Apollo Care is a program designed to establish and manage copay program deployment, optimizing patient access and affordability of Vevye
• PARx Solutions is a web-based technology stack designed to help prescribers–free of charge–overcome cumbersome, time-consuming challenges resulting from prior authorizations.

"Harrow was founded on a commitment to patient access. Our 360-degree approach to market access for Vevye, including these new partnerships with PhilRx, Apollo Care, and PARx, is designed to ensure that all patients who can benefit from Vevye and who are prescribed Vevye, can get Vevye, said Mark L. Baum, Chairman and Chief Executive Officer of Harrow. “We believe Vevye represents an important new prescription choice in the US dry eye disease market, and we are excited to streamline the prior authorization process, guiding patients through their insurance coverage and ensuring competitive pricing–with minimum hassle. Harrow’s Vevye market access program perfectly aligns with our commitment to providing physicians and their patients with innovative and affordable ophthalmic pharmaceutical products and the Harrow team eagerly anticipates the availability of Vevye – next week.”

For more information about Vevye, visit vevye.com.